On the contrary, NPM1-mutated MNs patients who are fit and candidate for undergoing more intensive treatments, potentially including allogeneic HSCT, may have improved survival outcomes compared with historical data, and could therefore benefit most from remission induction chemotherapy, rather than from MDS-directed therapeutic approaches, despite the presence of <20% blasts [5,79,87]. The gene discussed is NPM1; the disease is Melnick-Needles syndrome.